Filing Details

Accession Number:
0001447362-20-000276
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-09 17:24:54
Reporting Period:
2020-12-07
Accepted Time:
2020-12-09 17:24:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1447362 Castle Biosciences Inc CSTL Services-Medical Laboratories (8071) 770701774
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1783205 Iii C. Joseph Cook C/O Castle Biosciences, Inc.
820 S. Friendswood Drive, Suite 201
Friendswood TX 77546
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-12-07 2,600 $55.84 159,578 No 4 S Direct
Common Stock Disposition 2020-12-08 7,400 $55.98 152,178 No 4 S Direct
Common Stock Disposition 2020-12-08 27,176 $56.28 871,234 No 4 S Indirect See footnotes
Common Stock Disposition 2020-12-08 5,388 $56.23 865,846 No 4 S Indirect See footnotes
Common Stock Disposition 2020-12-08 4,612 $56.20 861,234 No 4 S Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 717 Indirect See footnotes
Footnotes
  1. These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020.
  2. This transaction was executed in multiple trades at prices ranging from $55.750 to $56.040, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $55.750 to $56.330, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This transaction was made pursuant to a Rule 10b5-1 plan adopted by MGC Venture Partners 2013, L.P. ("MGC 2013 LP") on August 13, 2020, as amended on September 10, 2020.
  5. This transaction was executed in multiple trades at prices ranging from $56.150 to $56.900, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. Held by MGC 2013 LP, MGC Venture Partners 2018, L.P. ("MGC 2018 LP"), MGC Venture Partners QP 2018, L.P. ("MGC 2018 QP LP") and MGC Venture Partners 2013 GP, LLC ("MGC 2013 GP"). MGC 2013 GP is the general partner of MGC 2013 LP. MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP LP.
  7. The Reporting Person is a managing director of MGC 2013 GP and a managing partner of MGC 2018 GP, and shares voting and investment power over the shares held by MGC 2013 LP, MGC 2018 LP, MGC 2018 QP LP and MGC 2013 GP. The Reporting Person disclaims beneficial ownership of the shares held by MGC 2013 GP, MGC 2018 GP, MGC 2013 LP, MGC 2018 LP and MGC 2018 QP LP as reported herein, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
  8. This transaction was made pursuant to a Rule 10b5-1 plan adopted by MGC 2018 QP LP on August 13, 2020, as amended on September 10, 2020.
  9. This transaction was executed in multiple trades at prices ranging from $56.150 to $56.455, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  10. This transaction was made pursuant to a Rule 10b5-1 plan adopted by MGC 2018 LP on August 13, 2020, as amended on September 10, 2020.
  11. This transaction was executed in multiple trades at prices ranging from $56.150 to $56.590, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  12. Held by MOD Partners, LLC ("MOD LLC"). The Reporting Person is the President and a member of MOD LLC and has voting and investment power over the shares held by MOD LLC. The Reporting Person disclaims beneficial ownership of the shares held by MOD LLC as reported herein, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.